Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
Predictive value of 68[Ga]Ga-DOTA-TATE PET/CT volumetric parameters in assessing treatment response to long-acting somatostatin analogues in patients with well-differentiated neuroendocrine tumours ; volume:14 ; number:1 ; day:13 ; month:11 ; year:2024 ; pages:1-12 ; date:12.2024
EJNMMI Research ; 14, Heft 1 (13.11.2024), 1-12, 12.2024
- Klassifikation
-
Medizin, Gesundheit
- Urheber
-
Morawiec-Sławek, Karolina
Opalińska, Marta
Lenda-Tracz, Wioletta
Sitarz, Katarzyna
Kurzyńska, Anna
Stefańska, Agnieszka
Kolasa, Magdalena
Sowa-Staszczak, Anna
Hubalewska-Dydejczyk, Alicja
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13550-024-01169-4
- URN
-
urn:nbn:de:101:1-2501311030567.161485620841
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:32 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Morawiec-Sławek, Karolina
- Opalińska, Marta
- Lenda-Tracz, Wioletta
- Sitarz, Katarzyna
- Kurzyńska, Anna
- Stefańska, Agnieszka
- Kolasa, Magdalena
- Sowa-Staszczak, Anna
- Hubalewska-Dydejczyk, Alicja
- SpringerLink (Online service)
Ähnliche Objekte (12)
![Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor](/assets/placeholder/searchResultMediaUnknown.png)
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1
Intraindividual comparison of [177Lu]Lu-DOTA-EB-TATE and [177Lu]Lu-DOTA-TOC
Comparison of 99mTc radiolabeled somatostatin antagonist with [68 Ga]Ga-DOTA-TATE in a patient with advanced neuroendocrine tumor
Relationships between uptake of [68Ga]Ga-DOTA-TATE and absorbed dose in [177Lu]Lu-DOTA-TATE therapy
Inter- and intra-tumoral heterogeneity on [68Ga]Ga-DOTA-TATE/[68Ga]Ga-DOTA-TOC PET/CT predicts response to [177Lu]Lu-DOTA-TATE PRRT in neuroendocrine tumor patients
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
Altered biodistribution of [68Ga]Ga-DOTA-TOC during somatostatin analogue treatment
PET-CT imaging of pulmonary inflammation using [68Ga]Ga-DOTA-TATE
CYP3A4 inhibitors do not influence [68Ga]Ga-DOTA-TATE uptake in liver tissue
The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors
Reduction of [68Ga]Ga-DOTA-TATE injected activity for digital PET/MR in comparison with analogue PET/CT
The somatostatin receptor 2 antagonist 64Cu-NODAGA-JR11 outperforms 64Cu-DOTA-TATE in a mouse xenograft model
Postoperative [68Ga]Ga-DOTA-TATE PET/CT imaging is prognostic for progression-free survival in meningioma WHO grade 1